Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell◆Adverse 8-K filing●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Oct 16, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Sep 24, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Aug 7, 2026Quarterly report · 10-QFiled by the company itself.Open the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record70617 flagged findings
Reported transactions (Form 4)80since Apr 26, 2023 · and 5 other holdings
Corporate events (8-K)30since May 14, 2018
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.
Identity
Formerly traded as LIFE.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-06-08listing compliance noticerecentOpen filing ↗“…a delisting notice and appeals the delisting determination by Nasdaq to the panel, such appeal would be successful. The Company…”
+1 more passage from the same document
- “…by the Compliance Date, the Staff will provide written notification that the Company’s common stock is subject to delisting. At…”
- 2026-06-08reverse splitrecentOpen filing ↗“…the Company meeting the continued listing requirement for market value of publicly held shares and all other initial listing…”
- 2026-05-15share offering or dilution eventrecentOpen filing ↗“…we have experienced a material decline in our stock price. If markets remain volatile or our stock price continues to remain…”
+1 more passage from the same document
- “…strategic partnering relationships to fund our operations.” Sources of Cash From our inception through March 31, 2026, we have…”
- 2026-05-15listing compliance noticerecentOpen filing ↗“…our common stock.* Our common stock is currently listed on The Nasdaq Capital Market. In order to maintain that listing, we must…”
+1 more passage from the same document
- “…stock and impede our ability to raise future capital. We may not be able to comply with all applicable listing requirements or…”
- 2026-05-15regulatory investigationrecentOpen filing ↗“…penalties; • suspend or withdraw regulatory approval; 35 • suspend any of our ongoing clinical trials; • refuse to approve pending…”
- 2026-05-15reverse splitrecentOpen filing ↗“…including patent or stockholder litigation; • if securities or industry analysts issue an adverse or misleading opinion regarding…”
+1 more passage from the same document
- “…be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
Listing notice in force
The exchange has notified the company that it fails a continued-listing requirement (8-K, item 3.01 of Jun 8, 2026).
The 25 most recent filings (of 706)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Oct 16, 268-K ↗Current report · Shareholder vote results new
- Oct 7, 26SCHEDULE 13G/A ↗Passive stake · Federated Hermes, Inc. · 5.1% · event on Sep 30, 26 · amendment
- Oct 1, 26Form 4 ↗Insider transaction
- Oct 1, 26Form 3 ↗Insider transaction
- Sep 24, 268-K ↗Current report · Other events
- Sep 11, 26DEF 14A ↗Shareholder meeting and votes
- Aug 31, 26PRE 14A ↗Shareholder meeting and votes
- Aug 7, 2610-Q ↗Quarterly report
- Aug 7, 268-K ↗Current report · Results
- Aug 6, 26SCHEDULE 13G/A ↗Passive stake · FMR LLC · 2.5% · event on Jun 30, 26 · amendment
- Jul 31, 268-K ↗Current report · A material agreement was terminated
- Jul 27, 26SCHEDULE 13G/A ↗Passive stake · BlackRock, Inc. · 1.8% · event on Jun 30, 26 · amendment
- Jul 8, 26SCHEDULE 13G/A ↗Passive stake · Federated Hermes, Inc. · 8.7% · event on Jun 30, 26 · amendment
- Jun 8, 268-K ↗Current report · Listing notice (8-K 3.01)
- Jun 5, 26SCHEDULE 13G/A ↗Passive stake · FMR LLC · 6.1% · event on May 29, 26 · amendment
- Jun 1, 268-K ↗Current report · Communication to the market
- May 28, 26Form 4 ↗Insider transaction
- May 15, 2610-Q ↗Quarterly report
- May 15, 268-K ↗Current report · Results
706 filings on record, the oldest from Jan 21, 15.
Listing the 25 most recent filings of the 706 on record.
62527
- Jul 31, 26A material agreement was terminated+1 more in the same filing8-K 1.02 ↗
- Jun 8, 26Listing notice (8-K 3.01)nominal item 3.01: the filing covers another matter8-K 3.01 ↗
- Dec 5, 25Listing notice (8-K 3.01)8-K 3.01 ↗
- Aug 7, 25Write-down of assets+1 more in the same filing8-K 2.06 ↗
- May 6, 25A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Dec 23, 24Entered a material agreement+1 more in the same filing8-K 1.01 ↗
3 senior executive changes2023 – 2024show all 3hide
- Dec 12, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- May 29, 24A senior executive left or was appointed+4 more in the same filing8-K 5.02 ↗
- May 19, 23A senior executive left or was appointed+4 more in the same filing8-K 5.02 ↗
- May 16, 22Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- Apr 29, 22A senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
- Apr 22, 22A material agreement was terminated+2 more in the same filing8-K 1.02 ↗
- Sep 14, 20Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- May 8, 20A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
13 older filings not shown · The record reaches back to Jun 18, 15.
Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.
- Feb 8, 19Listing notice (8-K 3.01)8-K 3.01 ↗
- Aug 14, 18Listing notice (8-K 3.01)+2 more in the same filing8-K 3.01 ↗
- May 14, 18Restructuring plan with committed costs+3 more in the same filing8-K 2.05 ↗
The full record holds 6 stress filings.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- The Vanguard Group5.2%Jun 30, 25SCHEDULE 13G ↗
- Federated Hermes, Inc.5.1%Sep 30, 26SCHEDULE 13G/A ↗5 co-filers on this document — the figure is the largest single stake, not their sum. · 3 earlier filings
- Point72 Asset Management, L.P.3.2%Mar 31, 25SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
- FMR LLC2.5%Jun 30, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- BlackRock, Inc.1.8%Jun 30, 26SCHEDULE 13G/A ↗1 earlier filing
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
- May 27, 26Buy$50KPAUL SCHIMMEL↗
- Feb 4, 26Sell$1KNANCY DENYESGeneral Counsel↗
- Feb 4, 26Sell$2KJill Marie BroadfootChief Financial Officer↗
- Feb 4, 26Sell$4KSanjay ShuklaPresident and CEO↗
- Oct 9, 25Buy$299KPAUL SCHIMMEL↗
- Oct 8, 25Buy$612KPAUL SCHIMMEL↗
- Mar 17, 25Buy$15KJane A Gross↗
- Feb 4, 25Sell$3KNANCY DENYESGeneral Counsel↗
- Feb 4, 25Sell$5KJill Marie BroadfootChief Financial Officer↗
- Jul 24, 24Buy$101KPAUL SCHIMMEL↗
- Jul 23, 24Buy$12KPAUL SCHIMMEL↗
- Jul 22, 24Buy$72KPAUL SCHIMMEL↗
There are 11 more transactions in this stretch.
Stock compensation, tax and giftsshow the 17 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Feb 3, 26Compensationamount n/aNANCY DENYESGeneral Counsel↗
- Feb 3, 26Compensationamount n/aJill Marie BroadfootChief Financial Officer↗
- Feb 3, 26Compensationamount n/aSanjay ShuklaPresident and CEO↗
- Feb 3, 25Compensationamount n/aNANCY DENYESGeneral Counsel↗
- Feb 3, 25Compensationamount n/aJill Marie BroadfootChief Financial Officer↗
- Feb 3, 25Compensationamount n/aSanjay ShuklaPresident and CEO↗
- Feb 5, 24Compensationamount n/aNANCY DENYESGeneral Counsel↗
- Feb 5, 24Compensationamount n/aJill Marie BroadfootChief Financial Officer↗
- Feb 5, 24Compensationamount n/aSanjay ShuklaPresident and CEO↗
- May 17, 23Giftamount n/aTIMOTHY COUGHLIN↗
- May 17, 23Giftamount n/aTIMOTHY COUGHLIN↗
- Apr 26, 23Compensationamount n/aTIMOTHY COUGHLIN↗
- Apr 26, 23Compensationamount n/aJane A Gross↗
- Apr 26, 23Compensationamount n/aSvetlana Lucas↗
- Apr 26, 23Compensationamount n/aPAUL SCHIMMEL↗
- Apr 26, 23Compensationamount n/aJOHN K CLARKE↗
- Apr 26, 23Compensationamount n/aSara Zaknoen↗
The full record holds 44 transactions and goes back to Feb 3, 23.
Its sector and its market
Atyr Pharma Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Atyr Pharma Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Atyr Pharma Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- Series with incidents in the period; the chart shows what could be kept.
- SEC records
- 706 documents on file, from Jan 21, 2015 to Oct 16, 2026.
- Company description
- Wikipedia, read on Sep 3, 2026.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.